Literature DB >> 9721868

The role of N-acetylation polymorphisms in smoking-associated bladder cancer: evidence of a gene-gene-exposure three-way interaction.

J A Taylor1, D M Umbach, E Stephens, T Castranio, D Paulson, C Robertson, J L Mohler, D A Bell.   

Abstract

Arylamines are known bladder carcinogens and are an important constituent of tobacco smoke. The handling of arylamines in the body is complex and includes metabolism by NAT1 and NAT2, enzymes that play a role in both activation and detoxification of arylamines and their congeners. Both NAT1 and NAT2 are polymorphic, with alleles that have been shown to correlate with higher or lower enzyme activity. To explore the combined role of these genes and exposure on bladder cancer risk, we examined the NAT1 and NAT2 genotype in a case-control study of bladder cancer in which detailed exposure histories were available on all 230 cases and 203 frequency-matched controls. Using PCR-RFLP genotyping, we determined NAT2 genotype for the five most common alleles, NAT2*4, NAT2*5, NAT2*6, NAT2*7, NAT2*14 (frequently referred to as WT, M1, M2, M3, and M4, respectively). Similarly, the NAT1 genotype was determined for the four most common alleles NAT1*3, NAT1*4, and NAT1*11, and the putative high-activity allele, NAT1*10. No association between NAT2 genotype and bladder cancer risk was found whether genotype was considered alone or in combination with smoking, in either stratified or logistic regression analysis that adjusted for age, sex, and race. Stratified and logistic regression analysis both demonstrated an increased risk for individuals carrying the NAT1*10 allele among smokers. There was evidence of a gene-dosage effect, such that those who were homozygous for the NAT1*10 allele had the highest risks. There was also evidence of a statistically significant gene-environment interaction, such that bladder cancer risk depends on both NAT1 genotype and smoking exposure. Interestingly, although NAT2 genotype did not influence risk either alone or in combination with smoking exposure, there was evidence of a statistically significant gene-gene-environment three-way interaction. Bladder cancer risk from smoking exposure is particularly high in those who inherit NAT2 slow alleles in combination with one or two copies of the NAT1*10 allele. A biological mechanism for this finding is suggested.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9721868

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  33 in total

1.  NAT2 slow acetylation, GSTM1 null genotype, and risk of bladder cancer: results from the Spanish Bladder Cancer Study and meta-analyses.

Authors:  Montserrat García-Closas; Núria Malats; Debra Silverman; Mustafa Dosemeci; Manolis Kogevinas; David W Hein; Adonina Tardón; Consol Serra; Alfredo Carrato; Reina García-Closas; Josep Lloreta; Gemma Castaño-Vinyals; Meredith Yeager; Robert Welch; Stephen Chanock; Nilanjan Chatterjee; Sholom Wacholder; Claudine Samanic; Montserrat Torà; Francisco Fernández; Francisco X Real; Nathaniel Rothman
Journal:  Lancet       Date:  2005 Aug 20-26       Impact factor: 79.321

2.  GSTM1 null and NAT2 slow acetylation genotypes, smoking intensity and bladder cancer risk: results from the New England bladder cancer study and NAT2 meta-analysis.

Authors:  L E Moore; D R Baris; J D Figueroa; M Garcia-Closas; M R Karagas; M R Schwenn; A T Johnson; J H Lubin; D W Hein; C L Dagnall; J S Colt; M Kida; M A Jones; A R Schned; S S Cherala; S J Chanock; K P Cantor; D T Silverman; N Rothman
Journal:  Carcinogenesis       Date:  2010-10-29       Impact factor: 4.944

3.  N-Acetyltransferase polymorphism and human cancer risk.

Authors:  X Yang; T Takeshita; K Morimoto
Journal:  Environ Health Prev Med       Date:  2000-01       Impact factor: 3.674

4.  The case-only independence assumption: associations between genetic polymorphisms and smoking among controls in two population-based studies.

Authors:  M Elizabeth Hodgson; Andrew F Olshan; Kari E North; Charles L Poole; Donglin Zeng; Chiu-Kit Tse; Tope O Keku; Joseph Galanko; Robert Sandler; Robert C Millikan
Journal:  Int J Mol Epidemiol Genet       Date:  2012-11-15

5.  Effect of NAT2 gene polymorphism on bladder cancer risk in Slovak population.

Authors:  Lucia Klimčáková; Viera Habalová; Monika Sivoňová; Vincent Nagy; Ján Šalagovič; Jozef Židzik
Journal:  Mol Biol Rep       Date:  2010-06-22       Impact factor: 2.316

6.  GENERAL THEORY FOR INTERACTIONS IN SUFFICIENT CAUSE MODELS WITH DICHOTOMOUS EXPOSURES.

Authors:  Tyler J VanderWeele; Thomas S Richardson
Journal:  Ann Stat       Date:  2012       Impact factor: 4.028

7.  Functional effects of genetic polymorphisms in the N-acetyltransferase 1 coding and 3' untranslated regions.

Authors:  Yuanqi Zhu; J Christopher States; Yang Wang; David W Hein
Journal:  Birth Defects Res A Clin Mol Teratol       Date:  2011-02-02

Review 8.  Localized bladder cancer.

Authors:  J I Izawa; H B Grossman
Journal:  Curr Treat Options Oncol       Date:  2000-12

9.  Genetic determinants in the metabolism of bladder carcinogens in relation to risk of bladder cancer.

Authors:  Jian-Min Yuan; Kenneth K Chan; Gerhard A Coetzee; J Esteban Castelao; Mary A Watson; Douglas A Bell; Renwei Wang; Mimi C Yu
Journal:  Carcinogenesis       Date:  2008-06-09       Impact factor: 4.944

10.  NAT1 polymorphisms and cancer risk: a systematic review and meta-analysis.

Authors:  Kunyi Zhang; Lijuan Gao; Yuqi Wu; Jianyi Chen; Chengguang Lin; Shaohua Liang; Jianxin Su; Jinming Ye; Xuyu He
Journal:  Int J Clin Exp Med       Date:  2015-06-15
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.